Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer
Adam J. Schoenfeld(Memorial Sloan Kettering Cancer Center), Matthew D. Hellmann(AstraZeneca (United States)), Jean‐Charles Soria(Inserm), M. Pérol(Centre Léon Bérard), Benjamin Solomon(Peter MacCallum Cancer Centre), Scott Antonia(Parker Institute for Cancer Immunotherapy), Martin Reck(German Center for Lung Research), Melissa L. Johnson(Tennessee Oncology), Solange Peters(University Hospital of Lausanne), Daniel S.W. Tan(Chinese Academy of Medical Sciences & Peking Union Medical College), Tony Mok(Chinese University of Hong Kong), Scott Gettinger(Yale Cancer Center), Christine M. Lovly(Dana-Farber Cancer Institute), Justin F. Gainor(Harvard University), F. Stephen Hodi(Harvard University), Mark M. Awad(Memorial Sloan Kettering Cancer Center), Enriqueta Felip(Institut Català d'Ornitologia), Natasha B. Leighl(Princess Margaret Cancer Centre)
Cited by 98
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k